The Market for Biosimilars Is Funky. The Industry Thinks PBM

Over the past year there’s been movement to rein in the three big PBMs, which face little regulation though they help set drug prices and drug choices for 80 percent of Americans and their doctors. The House voted Dec. 11, 320-71, for legislation that would require the PBMs to change some of the ways they […]

Related Keywords

United States , Americans , Abbvie Humira , Amgen Avsola , James Gelfand , Madelaine Feldman , Juliana Reed , Chris Phillips , Genentech Rituxan , Health News , Pfizer , Johnson , Coalition Of State Rheumatology Organizations , Biosimilars Forum , Care Management Association , American College Of Rheumatology , Industry Committee , Express Scripts , Pharmaceutical Care Management Association , American College , State Rheumatology ,